Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Summary

This study is designed to evaluate the efficacy of pamiparib in participants with metastatic castration-resistant prostate cancer (mCRPC) positive for circulating tumor cells (CTC) with homologous recombination deficiency (CTC-HRD). All participants will receive pamiparib. The purpose of this study is to demonstrate that pamiparib will improve Objective Response Rate (ORR) and Prostate-Specific Antigen (PSA) response rate

Timeline

Start

2019-02-05

Primary completion

2020-08-06

Completion

2020-09-02

Drugs

Indications